Forum Topics OCC OCC ASX Announcement

Pinned straw:

Last edited 5 months ago

ORTHOCELL ANNOUNCES FIRST US REMPLIR SALES REVENUE:

- Orthocell ha recorded its first US sales revenue from its flagship Remplir product.

- Revenue follows first surgical use of Remplir on June 25 in Ohio and subsequent early surgical cases in Florida sourced from the Company’s network of specialist distributors.

- Orthocell has transitioned from receipt of US FDA 510(k) clearance for Remplir to first revenue generation in just over 3 months.

- Early-stage surgeries conducted in out-patient day surgeries, known as Ambulatory Surgical Centers in the US, play a crucial strategic role in building experience and knowledge amongst the US surgical community in the significant US$1.6 Billion US market.

- Order fulfillment and associated customer invoicing workflow validated.

- Remplir US inventory held and shipped to customers by on-the-ground logistics partner Uniphar.

CEO/MD Paul Anderson: “We are confident our efforts in the US are on track to drive growth in sales of Remplir during the second half of calendar 2025.”

We shall see.

Held IRL

mikebrisy
Added 5 months ago

The desperation of announcing every activity in the US as “price sensitive” concerns me. I mean, a week or two ago it was “first procedure”, from which you’d hope first revenue would follow.

But as ever, I have to remind myself with these small caps, that management and boards often lack experience.

That said, it reflects poorly on the Board Chair that they aren’t coaching management to “stay calm and focused on the job.” I hope it’s not the chair that is driving the near-meaningless news flow! All this can be kept to the 4C IMHO.

I have high hopes for this $OCC, albeit with only a small position at this stage.

Disc: Held in RL and SM

28